Kitaghenda Fidele Kakule, Wang Jian, Li Tianci, Hong Jian, Yao Libin, Zhu Xiaocheng
Department of Gastrointestinal Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China.
Updates Surg. 2024 Dec;76(8):2841-2849. doi: 10.1007/s13304-024-01977-2. Epub 2024 Oct 15.
Wingless-type inducible signaling pathway protein-1 (WISP1) is a newly recognized adipokine, associated with obesity and type 2 diabetes (T2DM). This study aimed to investigate the effect of metabolic and bariatric surgery (MBS) on WISP1 circulating (serum) levels and tissue expression using rat models. We initially investigated whether WISP1 circulating levels were altered between the T2DM and normal rats. After confirmation, Sprague-Dawley (SD) rats were obtained and randomly divided as follows: Roux-en-Y gastric bypass (RYGB) group (n = 10), sleeve gastrectomy (SG) group (n = 10), SHAM group (n = 10), and normal control (NC) group (n = 10). Rats were followed for 8 weeks postoperatively. Preoperative and postoperative WISP1 circulating (serum) levels, glucose tolerance test (OGTT), insulin tolerance test (ITT), postoperative WISP1 expression (visceral adipose tissue, VAT; and skeletal muscle, SM), body weight, food intake, and fasting blood glucose levels were recorded. MBS significantly induced glucose control and weight loss. At postoperative week 8, WISP1 serum levels decreased in the MBS groups (P < 0.05); furthermore, WISP1 expression in VAT and SM significantly decreased in the RYGB and SG groups than SHAM (P < 0.05, and P < 0.05, respectively). Whereas the difference in the expression level between SG and RYGB did not amount to statistical significance (P > 0.05). MBS significantly decreased WISP1 serum levels, tissue expression in the VAT, and SM. As WISP1 is a regulator of low-grade inflammation associated with obesity and T2DM, further studies are needed to explore its relevance in MBS.
无翅型诱导信号通路蛋白-1（WISP1）是一种新发现的脂肪因子，与肥胖症和2型糖尿病（T2DM）相关。本研究旨在使用大鼠模型研究代谢减重手术（MBS）对WISP1循环（血清）水平和组织表达的影响。我们首先研究了T2DM大鼠和正常大鼠之间WISP1循环水平是否存在差异。确认后，获取Sprague-Dawley（SD）大鼠并随机分为以下几组：Roux-en-Y胃旁路术（RYGB）组（n = 10）、袖状胃切除术（SG）组（n = 10）、假手术组（n = 10）和正常对照组（NC）组（n = 10）。术后对大鼠进行8周的随访。记录术前和术后WISP1循环（血清）水平、葡萄糖耐量试验（OGTT）、胰岛素耐量试验（ITT）、术后WISP1表达（内脏脂肪组织，VAT；以及骨骼肌，SM）、体重、食物摄入量和空腹血糖水平。MBS显著改善了血糖控制并减轻了体重。术后第8周，MBS组的WISP1血清水平下降（P < 0.05）；此外，RYGB组和SG组VAT和SM中的WISP1表达明显低于假手术组（分别为P < 0.05和P < 0.05）。而SG组和RYGB组之间的表达水平差异无统计学意义（P > 0.05）。MBS显著降低了WISP1血清水平、VAT和SM中的组织表达。由于WISP1是与肥胖症和T2DM相关的低度炎症的调节因子，因此需要进一步研究以探讨其在MBS中的相关性。
